Experiments on mice with developed MASLD showed decreased expression of Treg and Th17 cells after the intraperitoneal administration of anti-CD25 and anti-IL-17 neutralizing antibodies. The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatotic liver disease.